Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $42

Benzinga Newsdesk www.benzinga.com Neutral 66.7%

Neg 0% Neu 66.7% Pos 0%

Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $20 to $42.